Photo by charlesdeluvio from unsplash
Anti‐CD38 antibodies such as daratumumab (DARA) are critical therapies for multiple myeloma and other diseases. Unfortunately, anti‐CD38 antibodies cause panreactivity in indirect antiglobulin tests (IATs), complicating blood compatibility testing. The… Click to show full abstract
Anti‐CD38 antibodies such as daratumumab (DARA) are critical therapies for multiple myeloma and other diseases. Unfortunately, anti‐CD38 antibodies cause panreactivity in indirect antiglobulin tests (IATs), complicating blood compatibility testing. The anti‐CD38 interference is most often mitigated by treating reagent red blood cells (RBCs) with dithiothreitol (DTT). However, when using the DTT method, not all RBC antibody specificities can be detected (e.g., anti‐K), and the DTT method is impractical for some transfusion services. We evaluated the ability of a new anti‐idiotype antibody to neutralize DARA in vitro and eliminate the anti‐CD38 interference.
Journal Title: Transfusion
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!